Looking for new blood and joint markers of joint damage in haemophilia
Studies gene activity in joint and blood samples from people with severe haemophilia.
Plain-language title generated from the registry record
Registry title: Identification of New Biomarkers in Haemophilic Arthropathy Through Transcriptome Analysis
Key facts
- Where
- Milan, ItalySee the site
Where in Italy
- Fondazione IRCCS Cà Granda Ospedale Maggiore PoliclinicoMilan, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- Trial code
- NCT07867821
- Record updated
- 9 October 2026
- Original description
Chronic arthropathy is one of the most common complications of haemophilia, affecting up to 90 per cent of patients aged 4 and over in at least one joint.Read full original descriptionShow less
Individuazione di Nuovi Biomarker Nell'Artropatia Emofilica Attraverso Analisi Del Trascrittoma - Identification of New Biomarkers in Haemophilic Arthropathy Through Transcriptome Analysis
Chronic arthropathy is one of the most common complications of haemophilia, affecting up to 90 per cent of patients aged 4 and over in at least one joint.
the study aims to assess gene expression in biological samples collected via synovectomy and joint replacement surgery, as well as in peripheral blood, in patients with severe haemophilia A or B; to compare these data with those from patients with osteoarthritis and rheumatoid arthritis; and to correlate the gene expression data with information relating to the clinical and laboratory phenotype, the history of inhibitors, and ultrasound and histological findings.
Inclusion: Diagnosis of severe haemophilia A or B; The need to perform therapeutic arthrocentesis, surgical synovectomy or orthopaedic joint replacement surgery for haemophilic arthropathy in all potentially affected joints; signed informed consent.
Exclusion: Current presence of an inhibitor (anti-FVIII or anti-FIX); Inability to give informed consent to participate in the study.